Dimethaid To Acquire Stake In Oxo Chemie
Dimethaid Research of Canada has entered into an agreement to acquire up to 25% of the common stock of Oxo Chemie of Switzerland, a research-based company and international pharmaceutical developer.
The Canadian firm will pay $5 million by July 31, 1996, for its stake in Oxo, and has the option to pay a further $22.5 million by June 30, 1997, to purchase a total of 25% of the Swiss company, which has offices in Germany, Thailand and the USA.
WF10: Potential Against AIDS Oxo has developed and holds the world rights to a new treatment for AIDS, WF10, which was recently studied in a Phase II clinical trial at the Vanderbilt University Hospital in Nashville, Tennesse, USA. The trial showed that WF10 effectively stimulates the immune systems of late-stage AIDS patients to resist life-threatening, opportunistic infections. The nine-month survival rate in the WF10 group was 90% versus 33% in the control group.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze